Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B

Table 1

Clinical demographics and clinical characteristics of patients in nonfibrosis and fibrosis groups.

	Total (N = 694)	Nonfibrosis (N = 376)	Fibrosis (N = 318)	value
Age, yr	43 (34, 55)	45 (39, 62)	40 (32, 48)	0.000
Male, N (%)	360 (52)	221 (61)	113 (34)	0.000
ALT, U/L	21 (11, 53)	42 (28, 168)	71 (30, 195)	0.000
AST, U/L	26 (19, 46)	28 (23, 132)	46 (28, 103)	0.000
BUN, mmol/L	4.4 ± 1.3	3.9 ± 1.0	4.7 ± 1.3	0.001
Cr, μmol/L	67 (57, 79)	63 (56, 77)	70 (58, 80)	0.001
RBC, 10^12/L	4.7 ± 0.5	4.7 ± 0.5	4.8 ± 0.5	0.108
PLT, 10^9/L	199 ± 61	227 ± 55	183 ± 59	0.000
WBC, 10^9/L	5.9 ± 3.1	6.4 ± 4.6	5.5 ± 1.5	0.105
Glucose, mmol/L	4.8 (4.4, 5.2)	5.1 (4.7, 5.1)	4.9 (4.5, 5.5)	0.017
sGDNF, pg/ml	25.2 (11.4, 29.5)	11.6 (7.2, 22.1)	28.4 (26.2, 31.6)	0.000

Nonfibrosis is defined by health controls and F0; fibrosis is defined by F1–F4.